Kadmon Holdings, the New York-based biotech, said Thursday that its experimental pill for chronic graft-versus-host disease achieved all the efficacy goals of a late-stage clinical trial.
Nearly 75% of the patients responded to treatment with the Kadmon drug, called KD025 — an improved result at the final analysis compared to interim findings disclosed last February.
About the Author Reprints
